Vall d'Hebron Institute of Oncology

Natural History of Rare Tumor Risk Syndromes: A Scoping Review to Inform Cost-Effectiveness Models

Background Hereditary cancer syndromes account for approximately 10% of all cancers. Many of these, classified as rare tumor risk syndromes (RTRS), lack comprehensive data on natural history, lifetime cancer risk, and the long-term impact of surveillance. These evidence gaps limi...

Enhancing learning health care systems with real-world data harmonization frameworks

The use of digital tools has enabled the capture of clinical data that can be leveraged to produce real-world evidence, complementing traditional trial data and addressing evidence gaps in oncology. Electronic health records offer rich, longitudinal data, although recording pract...

Targeted DNA Sequencing Reveals Distinct Rare-Variant Profiles in Pulmonary Hypertension Associated with Chronic Lung Diseases

The mechanisms underlying the development and severity of pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) remain poorly understood. To investigate the contribution of genetic factors, we performed targeted sequencing...

Prevalence of meeting aerobic physical activity and resistance training guidelines in advanced prostate cancer: a descriptive study of racial and regional disparities in the IRONMAN registry

Abstract Purpose To estimate guideline-based aerobic physical activity and resistance training participation in an international population of people with newly diagnosed metastatic hormone-sensitive or castration-resistant prostate cancer, and to assess racial and regional diffe...

Reappraisal of Cisplatin vs Carboplatin Treatment for Solid Tumors

Importance Cisplatin and carboplatin are central pillars of chemotherapy in solid tumor oncology, but their comparative efficacy and tolerability remain variably defined in the literature across tumor types and settings. Objective To quantify and grade the certainty of evidence c...

Randomised phase III trials of cancer prevention drugs: a systematic review and prediction of trial success

BACKGROUND: Pharmacological cancer risk reduction has received far less investment than therapeutic oncology and only a few agents have entered routine practice. Understanding the predictors of positive outcomes of previous trials and issues faced is critical to future developmen...

Validating the biological origin of in vivo fractional intracellular volume from VERDICT-MRI in the prostate

Abstract Objective Noninvasive microstructure estimates using magnetic resonance imaging (MRI) show potential in improving prostate cancer (PCa) diagnosis; however, histological validation is necessary. Materials and methods We used data from the Histo-MRI trial (NCT04792138). Pa...

Technical note: reconstructing dose distributions from manually planned electron boosts in breast radiotherapy

Purpose In breast radiotherapy, delivery of manually-calculated electron boosts limits retrospective dose–response analyses as dose distribution is unavailable. This work evaluates the feasibility of reconstructing dose distributions from manually planned electron boosts in breas...